CA2386759A1 - Usages therapeutiques des composes peroxometalliques - Google Patents

Usages therapeutiques des composes peroxometalliques Download PDF

Info

Publication number
CA2386759A1
CA2386759A1 CA002386759A CA2386759A CA2386759A1 CA 2386759 A1 CA2386759 A1 CA 2386759A1 CA 002386759 A CA002386759 A CA 002386759A CA 2386759 A CA2386759 A CA 2386759A CA 2386759 A1 CA2386759 A1 CA 2386759A1
Authority
CA
Canada
Prior art keywords
peroxide
composition
bpv
oxygen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386759A
Other languages
English (en)
Inventor
Robert Faure
Pierre Savard
Charles Doillon
Bruno Joseph Battistini
Martin Olivier
Barry Posner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
McGill University
Original Assignee
Universite Laval
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval, McGill University filed Critical Universite Laval
Priority to CA002386759A priority Critical patent/CA2386759A1/fr
Priority to CA002525672A priority patent/CA2525672A1/fr
Priority to PCT/CA2003/000738 priority patent/WO2003097068A1/fr
Priority to AU2003233285A priority patent/AU2003233285A1/en
Priority to EP03727051A priority patent/EP1511493A1/fr
Publication of CA2386759A1 publication Critical patent/CA2386759A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002386759A 2002-05-17 2002-05-17 Usages therapeutiques des composes peroxometalliques Abandoned CA2386759A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002386759A CA2386759A1 (fr) 2002-05-17 2002-05-17 Usages therapeutiques des composes peroxometalliques
CA002525672A CA2525672A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales
PCT/CA2003/000738 WO2003097068A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales
AU2003233285A AU2003233285A1 (en) 2002-05-17 2003-05-15 Use of peroxovanadium compounds as tumour cell growth suppressor
EP03727051A EP1511493A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002386759A CA2386759A1 (fr) 2002-05-17 2002-05-17 Usages therapeutiques des composes peroxometalliques

Publications (1)

Publication Number Publication Date
CA2386759A1 true CA2386759A1 (fr) 2003-11-17

Family

ID=29425956

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002386759A Abandoned CA2386759A1 (fr) 2002-05-17 2002-05-17 Usages therapeutiques des composes peroxometalliques
CA002525672A Abandoned CA2525672A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002525672A Abandoned CA2525672A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales

Country Status (4)

Country Link
EP (1) EP1511493A1 (fr)
AU (1) AU2003233285A1 (fr)
CA (2) CA2386759A1 (fr)
WO (1) WO2003097068A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487501B1 (fr) * 2001-10-09 2012-12-05 The Johns Hopkins University Phosphatase associee a une metastase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365122A1 (fr) * 1999-03-26 2000-10-05 Centre For Translational Research In Cancer Composes de peroxovanadium utilises comme agents antineoplasiques dans le traitement du cancer
CA2280249A1 (fr) * 1999-08-12 2001-02-12 Universite Laval Composes de vanadium utilises comme facteurs anti-angiogeniques et comme inhibiteurs de production d'endotheline

Also Published As

Publication number Publication date
EP1511493A1 (fr) 2005-03-09
AU2003233285A1 (en) 2003-12-02
CA2525672A1 (fr) 2003-11-27
WO2003097068A1 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
Zhou et al. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells
Teicher et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
AU2015289504B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Griffioen et al. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
Martellotta et al. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies
US9682121B2 (en) Application of irisin in myocardial ischemia reperfusion
US20140072635A1 (en) Thyroid hormone analogs and methods of use
JP2018533560A (ja) 癌を治療するための併用療法
US9421197B2 (en) Methods of generating hyper INOS expressing cells and uses thereof
CA2358212A1 (fr) Preparations destinees au traitement de maladies et procedes s'y rapportant
DK1848445T3 (en) Pharmaceutical composition and method of neoangiogenesis / revascularization useful in the treatment of ischemic heart disease
Boodhwani et al. Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress
EP1202728B1 (fr) Composes de peroxovanadium comme inhibiteurs de la proteine tyrosine phosphatase (ptp): leurs effets inhibiteurs sur l'angiogenese, la restenose et la production d'endothelines.
TWI469776B (zh) 有助於癌症之治療的方法，組成物以及製品
US20030055106A1 (en) Therapeutic uses of peroxometallic compounds
Fan et al. Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CA2386759A1 (fr) Usages therapeutiques des composes peroxometalliques
CA2314915A1 (fr) Composes de peroxovanadium comme inhibiteurs de la proteine tyrosine phosphatase (ptp) : leurs effets inhibiteurs sur l'angiogenese, la restenose et la production d'endothelines, et leurs effets stimulants sur la reponse immunitaire
Sun et al. Effects and mechanism of Pigeonpea (Cajanus cajan (L.) Millsp.) leaves on proliferation, migration, and tube formation of hypoxic human umbilical vein endothelial cells in vitro
US20220073642A1 (en) Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors
TWI822495B (zh) 用於治療肝細胞癌之包含魚針草內酯及安卓幸的組合物
CN113350346B (zh) 长春新碱在预防或治疗心肌纤维化中的应用
WO2003011217A9 (fr) Extraits de grifola et leurs procedes d'utilisation
Teicher 17 Potentiation of Cytotoxic Cancer

Legal Events

Date Code Title Description
FZDE Dead